Paper8137342
Pharmacokinetics and metabolism of anthracyclines.
Robert J and 1 other. Cancer Surv, 1993. Cited by 106 papers, by iCite.
Cite this record
ConductScience Library. Pharmacokinetics and metabolism of anthracyclines. Papers, record 8137342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8137342
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibiotics, Antineoplastic | Major topic |
| Neoplasms | Major topic |
| Drug Carriers | |
| Humans | |
| Immunotoxins | |
| Injections, Intra-Arterial |
Source PubMed
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 106 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42072389 | Development and Validation of an SPE-LC-MS Method for the Determination of Epirubicin, Olaparib and Ribociclib in Human Serum. | Biomedicines | 2026 | https://conductscience.org/library/papers/42072389 | PubMed |
| 41413110 | Liposomal co-delivery of β-carotene and doxorubicin for enhanced colorectal-cancer therapy. | Sci Rep | 2025 | https://conductscience.org/library/papers/41413110 | PubMed |
| 40481868 | Daunorubicin and its hydroxy metabolite in cardiomyocytes: insights into cellular kinetics, toxicity, DNA damage, and dexrazoxane-induced cardioprotection. | Arch Toxicol | 2025 | https://conductscience.org/library/papers/40481868 | PubMed |
| 37523060 | Targeted CRISPR activation and knockout screenings identify novel doxorubicin transporters. | Cell Oncol (Dordr) | 2023 | https://conductscience.org/library/papers/37523060 | PubMed |
| 37344500 | The dual role of ferroptosis in anthracycline-based chemotherapy includes reducing resistance and increasing toxicity. | Cell Death Discov | 2023 | https://conductscience.org/library/papers/37344500 | PubMed |
| 33572239 | Initial Identification of UDP-Glucose Dehydrogenase as a Prognostic Marker in Breast Cancer Patients, Which Facilitates Epirubicin Resistance and Regulates Hyaluronan Synthesis in MDA-MB-231 Cells. | Biomolecules | 2021 | https://conductscience.org/library/papers/33572239 | PubMed |
| 29108271 | Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/29108271 | PubMed |
| 28654865 | Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer. | Neoplasia | 2017 | https://conductscience.org/library/papers/28654865 | PubMed |
| 27100284 | CEST-MRI detects metabolite levels altered by breast cancer cell aggressiveness and chemotherapy response. | NMR Biomed | 2016 | https://conductscience.org/library/papers/27100284 | PubMed |
| 25940027 | Effect of age on drug metabolism in women with breast cancer. | Expert Opin Drug Metab Toxicol | 2015 | https://conductscience.org/library/papers/25940027 | PubMed |
| 25789218 | Synthesis and in vitro evaluation of amphiphilic peptides and their nanostructured conjugates. | Adv Pharm Bull | 2015 | https://conductscience.org/library/papers/25789218 | PubMed |
| 23928571 | Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice. | Anticancer Drugs | 2013 | https://conductscience.org/library/papers/23928571 | PubMed |
| 22178041 | Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. | J Vasc Interv Radiol | 2012 | https://conductscience.org/library/papers/22178041 | PubMed |
| 21656050 | Mechanisms and management of doxorubicin cardiotoxicity. | Herz | 2011 | https://conductscience.org/library/papers/21656050 | PubMed |
| 19711011 | Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. | Invest New Drugs | 2010 | https://conductscience.org/library/papers/19711011 | PubMed |
| 18754886 | Extracellular matrix proteins protect human HT1080 cells against the antimigratory effect of doxorubicin. | Cancer Sci | 2008 | https://conductscience.org/library/papers/18754886 | PubMed |
| 15141301 | Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis. | Cell Mol Life Sci | 2004 | https://conductscience.org/library/papers/15141301 | PubMed |
| 14970874 | N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. | Br J Cancer | 2004 | https://conductscience.org/library/papers/14970874 | PubMed |
| 10914552 | Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment. | Leukemia | 2000 | https://conductscience.org/library/papers/10914552 | PubMed |
| 10412894 | Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). | Eur J Drug Metab Pharmacokinet | 1999 | https://conductscience.org/library/papers/10412894 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP4F3 | 4051 | PubTator's text mining | https://conductscience.org/library/genes/4051 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8137342
GET https://conductscience.org/api/papers/v1/8137342/cited_by?page=2